Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LGND

Ligand Pharmaceuticals, Inc

Nov 14 • 04:00PM ET

200.86

-0.41 -0.20 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR VTI IWM VB VBR VXF SPSM IWN SCHA IJT

Scroll to Statements

Index	RUT	P/E	96.68	EPS (ttm)	2.08	Insider Own	2.43%	Shs Outstand	19.66M	Perf Week	-0.80%
Market Cap	3.95B	Forward P/E	25.16	EPS next Y	7.98	Insider Trans	-5.07%	Shs Float	19.20M	Perf Month	11.11%
Enterprise Value	3.74B	PEG	4.72	EPS next Q	1.55	Inst Own	102.08%	Short Float	5.77%	Perf Quarter	31.06%
Income	48.58M	P/S	15.74	EPS this Y	30.11%	Inst Trans	2.78%	Short Ratio	5.80	Perf Half Y	92.14%
Sales	251.23M	P/B	4.16	EPS next Y	6.90%	ROA	4.00%	Short Interest	1.11M	Perf YTD	87.46%
Book/sh	48.34	P/C	5.95	EPS next 5Y	20.47%	ROE	5.42%	52W High	212.49 -5.47%	Perf Year	66.36%
Cash/sh	33.76	P/FCF	129.02	EPS past 3/5Y	- -	ROIC	3.47%	52W Low	93.58 114.64%	Perf 3Y	166.92%
Dividend Est.	-	EV/EBITDA	57.46	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	81.19%	Volatility	3.84% 3.80%	Perf 5Y	280.67%
Dividend TTM	-	EV/Sales	14.89	EPS Y/Y TTM	-9.12%	Oper. Margin	11.48%	ATR (14)	7.21	Perf 10Y	230.23%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	24.30	Sales Y/Y TTM	64.83%	Profit Margin	19.34%	RSI (14)	60.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.69	EPS Q/Q	1559.91%	SMA20	3.52%	Beta	1.02	Target Price	229.29
Payout	-	Debt/Eq	0.47	Sales Q/Q	122.85%	SMA50	10.39%	Rel Volume	0.69	Prev Close	201.27
Employees	68	LT Debt/Eq	0.47	Earnings	Nov 06 BMO	SMA200	48.65%	Avg Volume	190.91K	Price	200.86
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.24% 96.55%	Trades		Volume	132,259	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169

Show Previous Ratings

Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
07:00AM	Loading…
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
04:01PM	Loading…
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Loading…
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
KOZARICH JOHN W	Director	Jan 17 '25	Option Exercise	52.30	2,406	125,834	46,181	Jun 02 08:05 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM
Espinoza Octavio	Chief Financial Officer	Dec 23 '24	Sale	116.37	2,104	244,850	20,647	Dec 26 08:32 PM
Espinoza Octavio	Officer	Dec 23 '24	Proposed Sale	116.37	2,104	244,851		Dec 23 08:19 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Option Exercise	52.30	2,406	125,834	31,921	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Sale	123.65	2,406	297,502	29,515	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 26 '24	Proposed Sale	119.19	2,406	286,771		Nov 27 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals, Inc

Upgrade your FINVIZ experience